Department of Biomedical Engineering, University of California, Davis, CA 95327, USA.
Ultrasound Med Biol. 2011 Jun;37(6):909-21. doi: 10.1016/j.ultrasmedbio.2011.03.001. Epub 2011 Apr 30.
We report a comparison between tumor perfusion estimates acquired using contrast-enhanced MRI and motion-corrected contrast-enhanced ultrasound before and after treatment with AG-028262, a potent vascular endothelial growth factor receptor tyrosine kinase inhibitor. Antiangiogenic activity was determined by assessing weekly ultrasound and MRI images of rats with bilateral hind flank mammary adenocarcinomas before and after treatment with AG-028262. Images were acquired with a spoiled gradient, 1.5 T magnetic resonance sequence and a destruction-replenishment ultrasound protocol. For ultrasound, a time to 80% contrast replenishment was calculated for each tumor voxel; for MR imaging, a measure of local flow rate was estimated from a linear fit of minimum to maximum intensities. AG-028262 significantly decreased tumor growth and increased the time required to replenish tumor voxels with an ultrasound contrast agent from 2.66 to 4.54 s and to fill with an MR contrast agent from 29.5 to 50.8 s. Measures of flow rate derived from MRI and ultrasound demonstrated a positive linear correlation of r2 = 0.86.
我们报告了使用对比增强 MRI 和运动校正对比增强超声在接受 AG-028262（一种有效的血管内皮生长因子受体酪氨酸激酶抑制剂）治疗前后获得的肿瘤灌注估计值之间的比较。通过评估双侧后肢乳腺腺癌大鼠在接受 AG-028262 治疗前后的每周超声和 MRI 图像来确定抗血管生成活性。使用带有破坏-补充超声方案的spoiled gradient，1.5 T 磁共振序列获取图像。对于超声，为每个肿瘤体素计算 80%对比度补充的时间；对于磁共振成像，从最小到最大强度的线性拟合来估计局部血流率的测量值。AG-028262 显著降低了肿瘤生长，并将用超声造影剂补充肿瘤体素所需的时间从 2.66 秒增加到 4.54 秒，并用 MR 造影剂填充所需的时间从 29.5 秒增加到 50.8 秒。来自 MRI 和超声的血流率测量值显示出 r2 = 0.86 的正线性相关。
